Canary Speech, a leading AI-powered voice biomarker health tech company, announced it has secured a $13 million Series A funding round led by Cortes Capital, LLC (Love’s Private Equity), with participation from Sorenson Communications, LLC., SMK (Japan), and Hackensack Meridian Health.
With solid patent positioning, Canary is at the industry forefront with nine issued patents protecting the use of vocal biomarkers within healthcare. And Canary aims to expand its team to support the accelerating growth driven by advancements in artificial intelligence and the healthcare industry’s demand for more advanced tools.
Canary’s vocal biomarker technology has a wide range of applications within the healthcare industry. And these applications include contact centers, ambient clinical listening, remote patient monitoring, and annual wellness checks. Ambient listening tools – which are systems built to capture and analyze conversations in real-time – enable healthcare providers to focus on patient interactions while automatically documenting clinical notes.
Canary’s vocal biomarker technology enhances these tools by adding real-time screening for behavioral and cognitive conditions, offering clinicians with critical additional data that was previously unavailable. And through an extensive network of partnerships, both with telehealth organizations and health systems, Canary is prepared to rapidly scale its cloud-based data processing capabilities. With ambient listening, Canary can assess patients’ health and simultaneously evaluate physicians’ health, enabling healthcare systems to proactively support their care teams.
KEY QUOTE:
“There are technologies that truly disrupt the way healthcare is administered, and Canary is committed to pioneering vocal biomarkers and ambient listening for the betterment of healthcare.”
- Henry O’Connell, co-founder and CEO of Canary Speech
“We couldn’t be more excited to support Canary Speech’s mission to drive change in the healthcare industry with their scalable technology and best-in-class team.”
- Ryan Tidwell, Chief Investment Officer at Cortes Capital
